{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"KPTI","limit":50},"count":50,"signals":[{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":22,"context":"ritories and countries outside the U.S. and is commercially available in a growing number of countries as our partners continue to secure reimbursement approvals.  In September 2025, we completed enrollment in our ongoing Phase 3 clinical trial to evaluate the efficacy and safety of once-weekly selinexor in combination with ruxolitinib versus placebo plus ruxolitinib in JAK2 inhibitor (JAKi)-naive my","filed_date":"2026-02-13","accession":"0001193125-26-049397","full_text":"https://origin.rootz.global/static/filing/0001193125-26-049397.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":101,"context":"reporting and payment obligations under governmental drug pricing programs, applicable healthcare, privacy and data security laws and environmental, health and safety laws and regulations may have a material adverse effect on our business, financial condition or results of operations. 4 [Table of Contents](#toc_page) Changes in U.S. and international trade policy could have a material adverse impact on our business, fi","filed_date":"2026-02-13","accession":"0001193125-26-049397","full_text":"https://origin.rootz.global/static/filing/0001193125-26-049397.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":41,"context":"to delay, reduce or eliminate our research and development programs or any current or future commercialization efforts for one or more of our products or product candidates, any of which could have a material adverse effect on our business, operating results and prospects.  We are continuing to evaluate strategic alternatives, which may include a potential merger or sale of the Company; in or out of court restructurings","filed_date":"2025-11-03","accession":"0001193125-25-261667","full_text":"https://origin.rootz.global/static/filing/0001193125-25-261667.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":37,"context":"losing Date, no fact, circumstance, occurrence, change or event has occurred that constitutes, or would reasonably be expected to individually or in the aggregate, in material adverse change in, or a material adverse effect on, the operations, business, properties or financial condition so the Credit Parties, taken as a whole.  (e) that the information included in the Collateral Questionnaire delivered to the Administra","filed_date":"2025-10-14","accession":"0001193125-25-239015","full_text":"https://origin.rootz.global/static/filing/0001193125-25-239015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":40,"context":"to delay, reduce or eliminate our research and development programs or any current or future commercialization efforts for one or more of our products or product candidates, any of which could have a material adverse effect on our business, operating results and prospects.  We are evaluating strategic alternatives, which may include a potential merger or sale of the Company; in or out of court restructurings; repurchase","filed_date":"2025-08-11","accession":"0000950170-25-106238","full_text":"https://origin.rootz.global/static/filing/0000950170-25-106238.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":39,"context":"ffects that prevented further development of the compound. If such an event occurs after any of our or our collaborators product candidates are approved and/or commercialized, a number of potentially significant negative consequences may result, including:  regulatory authorities may withdraw the approval of such drug, require additional warnings on the label or impose distribution or use restrictions and/or require one or more","filed_date":"2025-05-12","accession":"0000950170-25-069231","full_text":"https://origin.rootz.global/static/filing/0000950170-25-069231.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":23,"context":"ity Incentive Plan, as amended, to increase the number of shares of our common stock available for issuance thereunder by 450,000 shares; (3) To approve, on an advisory basis, the compensation of our named executive officers, as described in this proxy statement; (4) To recommend, on an advisory basis, the frequency of future non-binding advisory votes on the compensation of our named executive officers; (5) To ratify t","filed_date":"2025-04-14","accession":"0000950170-25-053511","full_text":"https://origin.rootz.global/static/filing/0000950170-25-053511.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"endpoint, we increased the total sample size from 306 patients to 350 patients in order to analyze the new co-primary endpoint, Abs-TSS, in a sufficient number of patients. We expect to complete enrollment of the SENTRY Trial in the first half of 2025 and report top-line data in the second half of 2025. Our evaluation of selinexor to treat patients with myelofibrosis is supported by the Phase 1 part","filed_date":"2025-02-19","accession":"0000950170-25-022765","full_text":"https://origin.rootz.global/static/filing/0000950170-25-022765.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":95,"context":"reporting and payment obligations under governmental drug pricing programs, applicable healthcare, privacy and data security laws and environmental, health and safety laws and regulations may have a material adverse effect on our business, financial condition or results of operations. Changes in U.S. and international trade policies, particularly with respect to China, may adversely impact our business.  We may not be","filed_date":"2025-02-19","accession":"0000950170-25-022765","full_text":"https://origin.rootz.global/static/filing/0000950170-25-022765.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":38,"context":"ffects that prevented further development of the compound. If such an event occurs after any of our or our collaborators product candidates are approved and/or commercialized, a number of potentially significant negative consequences may result, including:  regulatory authorities may withdraw the approval of such drug, require additional warnings on the label or impose distribution or use restrictions and/or require one or more","filed_date":"2024-11-05","accession":"0000950170-24-121076","full_text":"https://origin.rootz.global/static/filing/0000950170-24-121076.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":39,"context":"ffects that prevented further development of the compound. If such an event occurs after any of our or our collaborators product candidates are approved and/or commercialized, a number of potentially significant negative consequences may result, including:  regulatory authorities may withdraw the approval of such drug, require additional warnings on the label or impose distribution or use restrictions and/or require one or more","filed_date":"2024-08-06","accession":"0000950170-24-091210","full_text":"https://origin.rootz.global/static/filing/0000950170-24-091210.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"son of movements in price exceeding limits permitted by the relevant stock exchange or otherwise) in the Common Stock or in any options contracts or futures contracts relating to the Common Stock.  **Material Adverse Effect** means, with respect to the Note Parties, (a) a material adverse change in, or a material adverse effect on, the operations, business, properties, prospects or financial condition of such Persons, t","filed_date":"2024-05-14","accession":"0001193125-24-138211","full_text":"https://origin.rootz.global/static/filing/0001193125-24-138211.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":37,"context":"ffects that prevented further development of the compound. If such an event occurs after any of our or our collaborators product candidates are approved and/or commercialized, a number of potentially significant negative consequences may result, including:  regulatory authorities may withdraw the approval of such drug, require additional warnings on the label or impose distribution or use restrictions and/or require one or more","filed_date":"2024-05-08","accession":"0000950170-24-055672","full_text":"https://origin.rootz.global/static/filing/0000950170-24-055672.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":16,"context":"for issuance thereunder by 5,000,000 shares; (4) To approve a one-time stock option exchange program for non-executive officer employees; (5) To approve, on an advisory basis, the compensation of our named executive officers, as described in this proxy statement; (6) To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2024; and (7) To consi","filed_date":"2024-04-19","accession":"0000950170-24-045717","full_text":"https://origin.rootz.global/static/filing/0000950170-24-045717.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":89,"context":"reporting and payment obligations under governmental drug pricing programs, applicable healthcare, privacy and data security laws and environmental, health and safety laws and regulations may have a material adverse effect on our business, financial condition or results of operations. We may never achieve or maintain profitability and will need additional funding to achieve our business objectives.  We may not be able","filed_date":"2024-02-29","accession":"0000950170-24-022650","full_text":"https://origin.rootz.global/static/filing/0000950170-24-022650.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":31,"context":"hat prevented further development of the compound. If such an event occurs after any of our or our collaborators&#x2019; product candidates are approved and/or commercialized, a number of potentially significant negative consequences may result, including:  &#x2022; regulatory authorities may withdraw the approval of such drug;  &#x2022; regulatory authorities may require additional warnings on the label or impose distribution o","filed_date":"2023-11-02","accession":"0000950170-23-057754","full_text":"https://origin.rootz.global/static/filing/0000950170-23-057754.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":30,"context":"hat prevented further development of the compound. If such an event occurs after any of our or our collaborators&#x2019; product candidates are approved and/or commercialized, a number of potentially significant negative consequences may result, including:  &#x2022; regulatory authorities may withdraw the approval of such drug;  &#x2022; regulatory authorities may require additional warnings on the label or impose distribution o","filed_date":"2023-08-02","accession":"0000950170-23-036780","full_text":"https://origin.rootz.global/static/filing/0000950170-23-036780.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":30,"context":"hat prevented further development of the compound. If such an event occurs after any of our or our collaborators&#x2019; product candidates are approved and/or commercialized, a number of potentially significant negative consequences may result, including:  &#x2022; regulatory authorities may withdraw the approval of such drug;  &#x2022; regulatory authorities may require additional warnings on the label or impose distribution o","filed_date":"2023-05-04","accession":"0000950170-23-017483","full_text":"https://origin.rootz.global/static/filing/0000950170-23-017483.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":25,"context":"amendment to our Restated Certificate of Incorporation, as amended, to reflect new Delaware law provisions regarding officer exculpation; (6) To approve, on an advisory basis, the compensation of our named executive officers, as described in this proxy statement; (7) To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2023; and (8) To consi","filed_date":"2023-04-11","accession":"0000950170-23-012367","full_text":"https://origin.rootz.global/static/filing/0000950170-23-012367.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":33,"context":"reporting and payment obligations under governmental drug pricing programs, applicable healthcare, privacy and data security laws and environmental, health and safety laws and regulations may have a material adverse effect on our business, financial condition or results of operations. &#x2022; We may never achieve or maintain profitability and will need additional funding to achieve our business objectives.  &#x2022; W","filed_date":"2023-02-17","accession":"0000950170-23-003129","full_text":"https://origin.rootz.global/static/filing/0000950170-23-003129.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":28,"context":"hat prevented further development of the compound. If such an event occurs after any of our or our collaborators&#x2019; product candidates are approved and/or commercialized, a number of potentially significant negative consequences may result, including:  &#x2022; regulatory authorities may withdraw the approval of such drug;  &#x2022; regulatory authorities may require additional warnings on the label or impose distribution o","filed_date":"2022-11-03","accession":"0000950170-22-021917","full_text":"https://origin.rootz.global/static/filing/0000950170-22-021917.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":28,"context":"hat prevented further development of the compound. If such an event occurs after any of our or our collaborators&#x2019; product candidates are approved and/or commercialized, a number of potentially significant negative consequences may result, including:  &#x2022; regulatory authorities may withdraw the approval of such drug;  &#x2022; regulatory authorities may require additional warnings on the label or impose distribution o","filed_date":"2022-08-04","accession":"0000950170-22-014788","full_text":"https://origin.rootz.global/static/filing/0000950170-22-014788.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":28,"context":"hat prevented further development of the compound. If such an event occurs after any of our or our collaborators&#x2019; product candidates are approved and/or commercialized, a number of potentially significant negative consequences may result, including:  &#x2022; regulatory authorities may withdraw the approval of such drug;  &#x2022; regulatory authorities may require additional warnings on the label or impose distribution o","filed_date":"2022-05-05","accession":"0000950170-22-007564","full_text":"https://origin.rootz.global/static/filing/0000950170-22-007564.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":22,"context":"til their resignation or removal or until their successors are duly elected and qualified: Garen G. Bohlin and Peter Honig, M.D., M.P.H.; (2) To approve, on an advisory basis, the compensation of our named executive officers, as described in this proxy statement; (3) To approve the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan;  (4) To ratify the appointment of Ernst & Young LLP as our independent registered p","filed_date":"2022-04-08","accession":"0000950170-22-005492","full_text":"https://origin.rootz.global/static/filing/0000950170-22-005492.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":33,"context":"e anti-kickback, fraud and abuse and other healthcare laws and regulations; (iv) global privacy and data security requirements; or (v) environmental, health and safety laws and regulations may have a material adverse effect on our business, financial condition or results of operations.  &#x2022; Our employees, independent contractors, consultants, collaborators and vendors may engage in misconduct or other improper acti","filed_date":"2022-03-01","accession":"0000950170-22-002548","full_text":"https://origin.rootz.global/static/filing/0000950170-22-002548.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"d stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.  Any failure, delay or setback in obtaining regulatory approval for our or our collaborators&#x2019; product candidates could materially adversely affect our or our collaborators&#x2","filed_date":"2021-11-03","accession":"0000950170-21-002729","full_text":"https://origin.rootz.global/static/filing/0000950170-21-002729.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"d stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.  Any failure, delay or setback in obtaining regulatory approval for our or our collaborators&#x2019; product candidates could materially adversely affect our or our collaborators&#x2","filed_date":"2021-08-05","accession":"0000950170-21-000948","full_text":"https://origin.rootz.global/static/filing/0000950170-21-000948.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"d stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.  Any failure, delay or setback in obtaining regulatory approval for our or our collaborators&#x2019; product candidates could materially adversely affect our or our collaborators&#x2","filed_date":"2021-05-04","accession":"0000950170-21-000073","full_text":"https://origin.rootz.global/static/filing/0000950170-21-000073.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":16,"context":"sors are duly elected and qualified: Deepika R. Pakianathan, Ph.D., Richard Paulson, M.B.A., and Chen Schor, M.B.A., C.P.A.; | | |  |  (2) |  To approve, on an advisory basis, the compensation of our named executive officers, as described in this proxy statement; | | |  |  (3) |  To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2021; and","filed_date":"2021-04-07","accession":"0001193125-21-108899","full_text":"https://origin.rootz.global/static/filing/0001193125-21-108899.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":27,"context":"ble anti-kickback, fraud and abuse and other healthcare laws and regulations; (iv)global privacy and data security requirements; or (v)environmental, health and safety laws and regulations may have a material adverse effect on our business, financial condition or results of operations. | | |  |  |  |  Our employees, independent contractors, consultants and vendors may engage in misconduct or other improper activities, w","filed_date":"2021-02-24","accession":"0001193125-21-054811","full_text":"https://origin.rootz.global/static/filing/0001193125-21-054811.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":22,"context":"ndon or limit the development or commercialization of one or more of our drugs or drug candidates, and such findings may delay or prevent regulatory approval, limit commercial viability, or result in significant negative consequences following any marketing approval.  Four of our drug candidates are in clinical development for the treatment of human diseases. Their risk of failure is high. If our current or future indications of","filed_date":"2020-11-02","accession":"0001564590-20-049664","full_text":"https://origin.rootz.global/static/filing/0001564590-20-049664.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"acebo After Combination Chemotherapy In Patients with Advanced or Recurrent ENDOmetrial Cancer) study evaluating selinexor as maintenance therapy in endometrial cancer. We have recently completed enrollment in the Phase 3 portion of the SEAL study and currently anticipate topline data in the second half of 2020. As a result of the positive results from STORM, in addition to the FDA approval of our fi","filed_date":"2020-08-04","accession":"0001564590-20-036120","full_text":"https://origin.rootz.global/static/filing/0001564590-20-036120.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":22,"context":"ndon or limit the development or commercialization of one or more of our drugs or drug candidates, and such findings may delay or prevent regulatory approval, limit commercial viability, or result in significant negative consequences following any marketing approval.  Four of our drug candidates are in clinical development for treatment of human diseases. Their risk of failure is high. If our current or future indications of XPO","filed_date":"2020-08-04","accession":"0001564590-20-036120","full_text":"https://origin.rootz.global/static/filing/0001564590-20-036120.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":22,"context":"ed to abandon or limit the development or commercialization of one or more of our drug candidates, and such findings may delay or prevent regulatory approval, limit commercial viability, or result in significant negative consequences following any marketing approval.  Four of our drug candidates are in clinical development for treatment of human diseases. Their risk of failure is high. If XPOVIO or any of our drug candidates are","filed_date":"2020-05-05","accession":"0001193125-20-133703","full_text":"https://origin.rootz.global/static/filing/0001193125-20-133703.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":44,"context":"ntil their resignation or removal or until their successors are duly elected and qualified: Barry E. Greene and Mansoor Raza Mirza, M.D.;  2. To approve, on an advisory basis, the compensation of our named executive officers, as described in this proxy statement;  3. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2020; and  4. To consi","filed_date":"2020-04-09","accession":"0001193125-20-102581","full_text":"https://origin.rootz.global/static/filing/0001193125-20-102581.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"luating once-weekly selinexor in combination with once-weekly Velcade and dexamethasone (SVd) for the treatment of patients with multiple myeloma who have had one to three prior lines of therapy. Enrollment in the BOSTON study was completed in January 2019 and  top-line data are expected in early 2020, contingent upon the occurrence of progression-free survival, or PFS, events, the primary endpoint o","filed_date":"2020-02-26","accession":"0001193125-20-049115","full_text":"https://origin.rootz.global/static/filing/0001193125-20-049115.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"ed to abandon or limit the development or commercialization of one or more of our drug candidates, and such findings may delay or prevent regulatory approval, limit commercial viability, or result in significant negative consequences following any marketing approval.  Four of our drug candidates are in clinical development for treatment of human diseases. Their risk of failure is high. If XPOVIO or any of our drug candidates are","filed_date":"2020-02-26","accession":"0001193125-20-049115","full_text":"https://origin.rootz.global/static/filing/0001193125-20-049115.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":22,"context":"f our drug candidates, we may need to abandon or limit the development of one or more of our drug candidates or it could delay or prevent regulatory approval, limit commercial viability, or result in significant negative consequences following any marketing approval.  Four of our drug candidates are in clinical development for treatment of human diseases. Their risk of failure is high. If XPOVIO or any of our drug candidates are","filed_date":"2019-11-04","accession":"0001193125-19-282510","full_text":"https://origin.rootz.global/static/filing/0001193125-19-282510.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":21,"context":"f our drug candidates, we may need to abandon or limit the development of one or more of our drug candidates or it could delay or prevent regulatory approval, limit commercial viability, or result in significant negative consequences following any marketing approval.  Four of our drug candidates are in clinical development for treatment of human diseases. Their risk of failure is high. If XPOVIO or any of our drug candidates are","filed_date":"2019-08-07","accession":"0001193125-19-215344","full_text":"https://origin.rootz.global/static/filing/0001193125-19-215344.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":19,"context":"f our drug candidates, we may need to abandon or limit the development of one or more of our drug candidates or it could delay or prevent regulatory approval, limit commercial viability, or result in significant negative consequences following any marketing approval.** Four of our drug candidates are in clinical development for treatment of human diseases. Their risk of failure is high. It is impossible to predict when or if any","filed_date":"2019-05-09","accession":"0001193125-19-142973","full_text":"https://origin.rootz.global/static/filing/0001193125-19-142973.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":54,"context":"s:  1. To elect three Class III directors to serve for a three-year term to expire at the 2022 annual meeting of stockholders;  2. To approve, on a non-binding advisory basis, the compensation of our named executive officers, as described in the Compensation Discussion and Analysis, executive compensation tables and accompanying narrative disclosures in this proxy statement;  3. To recommend, on a non-binding advisory b","filed_date":"2019-04-19","accession":"0001193125-19-112369","full_text":"https://origin.rootz.global/static/filing/0001193125-19-112369.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"ion, we plan to work with the FDA to evaluate the best path forward as it continues to review our NDA requesting accelerated approval of selinexor. In January 2019, we announced the completion of enrollment of our BOSTON study, and we anticipate top-line data from the BOSTON study at the earliest by the end of 2019 or into 2020 depending on the occurrence of progression events per protocol.  Provided","filed_date":"2019-02-28","accession":"0001193125-19-057610","full_text":"https://origin.rootz.global/static/filing/0001193125-19-057610.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":19,"context":"f our drug candidates, we may need to abandon or limit the development of one or more of our drug candidates or it could delay or prevent regulatory approval, limit commercial viability, or result in significant negative consequences following any marketing approval.** Four of our drug candidates are in clinical development for treatment of human diseases. Their risk of failure is high. It is impossible to predict when or if any","filed_date":"2019-02-28","accession":"0001193125-19-057610","full_text":"https://origin.rootz.global/static/filing/0001193125-19-057610.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":15,"context":"r own reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved drugs that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize drugs and our overall financial condition.  **Product liability lawsuits against us could cause us to incur substantial","filed_date":"2018-11-08","accession":"0001193125-18-322696","full_text":"https://origin.rootz.global/static/filing/0001193125-18-322696.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":33,"context":"d in the Registration Statement and the Prospectus, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect or would reasonably be expected to have a material adverse effect on or affecting the assets, business, operations, earnings, properties, condition (financial or otherwise), prospects, stockholders e","filed_date":"2018-08-17","accession":"0001193125-18-251656","full_text":"https://origin.rootz.global/static/filing/0001193125-18-251656.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":14,"context":"r own reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved drugs that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize drugs and our overall financial condition.  **Product liability lawsuits against us could cause us to incur substantial","filed_date":"2018-08-07","accession":"0001193125-18-241301","full_text":"https://origin.rootz.global/static/filing/0001193125-18-241301.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"r own reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved drugs that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize drugs and our overall financial condition.  **Product liability lawsuits against us could cause us to incur substantial","filed_date":"2018-05-10","accession":"0001193125-18-159200","full_text":"https://origin.rootz.global/static/filing/0001193125-18-159200.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":49,"context":"hange Act of 1934, as amended, or the Exchange Act. In addition, as an emerging growth company, we are not required to conduct votes seeking approval, on an advisory basis, of the compensation of our named executive officers or the frequency with which such votes must be conducted. We will remain an emerging growth company until the earliest of (i) the last day of the fiscal year in which we have total annual gross reve","filed_date":"2018-04-27","accession":"0001193125-18-138840","full_text":"https://origin.rootz.global/static/filing/0001193125-18-138840.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"inistered with KPT-9274 and may improve tolerability, particularly with respect to anemia. Dose escalation remains ongoing and further evaluation of effects in NAPRT1 deficient tumors is planned. Enrollment is planned to continue based on the patients NAPRT1 status in a 2:1 ratio (NAPRT1- : NAPRT1+). These study findings indicate that in patients whose disease has progressed despite most available th","filed_date":"2018-03-15","accession":"0001193125-18-084024","full_text":"https://origin.rootz.global/static/filing/0001193125-18-084024.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"KPTI","company":"Karyopharm Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"r own reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved drugs that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize drugs and our overall financial condition.  **Product liability lawsuits against us could cause us to incur substantial","filed_date":"2018-03-15","accession":"0001193125-18-084024","full_text":"https://origin.rootz.global/static/filing/0001193125-18-084024.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"92a72ced4b143ab916f0b3085757c74053694b70023fcf1be996c5e4911bf013","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"6de12826613ccd2197ec8cf5a467bc844e163121a9ed1c202e84a5aaee634dc7","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":86,"hourly_limit":500,"remaining":414,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}